|
시장보고서
상품코드
2024926
망막아세포종 치료 시장 규모, 점유율, 동향 및 예측 : 유형별, 치료법별, 병기 분류별, 용도별, 지역별(2026-2034년)Retinoblastoma Treatment Market Size, Share, Trends and Forecast by Type, Treatment Type, Type of Staging, Application, and Region, 2026-2034 |
||||||
2025년의 세계 망막아세포종 치료 시장 규모는 31억 달러로 평가되었습니다. 향후에 대해 IMARC Group은 2026-2034년에 CAGR 3.38%로 추이하며, 2034년까지 시장 규모가 42억 달러에 달할 것으로 예측하고 있습니다. 현재 아시아태평양이 시장을 주도하고 있습니다. 안과 치료에 대한 의료비 증가, 부작용이 적은 치료법 연구개발(R&D)에 대한 투자 확대, 건강에 대한 인식 증가 등이 이 지역의 시장 성장을 촉진하는 주요 요인으로 작용하고 있습니다.
망막모세포종은 일반적으로 5세 미만의 어린이에게 발생하는 가장 흔한 암 중 하나입니다. 망막모세포종의 증상으로는 '고양이 눈 반사' 또는 '백내장'이라고 불리는 동공이 하얗게 보이는 현상 등이 있습니다. 망막모세포종은 초기 단계라면 완치가 가능하므로 다양한 약물전달법이나 화학요법을 통해 치료할 수 있으며, 단기적으로는 어느 정도 효과를 기대할 수 있습니다. 1차 또는 2차 항암화학요법 종료 후 종양의 축소 정도와 안구내 위치에 따라 다양한 국소치료가 적용됩니다. 다양한 치료법을 병용하는 것이 망막모세포종 치료에서 가장 높은 성공률을 보이는 치료법입니다. 수술은 망막에서 종양을 완전히 제거하므로 망막모세포종에 대한 근본적인 치료법입니다. 망막모세포종의 자세한 진단을 위해 초음파 검사, CT 검사, MRI, X-선 검사, 뼈 스캔 등 다양한 영상 검사를 시행할 수 있습니다.
망막모세포종 치료제 시장 동향:
안과 치료에 소요되는 의료비용의 대폭적인 증가는 시장을 촉진하는 중요한 요인이 되고 있습니다. 이는 젊은 층의 망막모세포종 발생률 증가에 기인하는 것으로 추정됩니다. 이에 따라 부작용이 적고 보다 새롭고 효율적인 치료 전략에 초점을 맞춘 연구개발(R&D) 활동에 대한 투자가 증가하고 있으며, 이는 시장의 원동력이 되고 있습니다. 또한 다양한 유형의 암에 대한 인식이 높아지면서 진단율과 치료율이 증가하고 있는 것도 중요한 성장 요인으로 작용하고 있습니다. 그러나 각종 망막모세포종 치료제의 접근성 어려움과 엄격한 의약품 규제가 시장 성장을 저해하는 요인으로 작용하고 있습니다. 한편, 제품 승인 건수의 증가와 함께 신약 출시가 진행되고 있는 것은 시장에 밝은 전망을 가져다주고 있습니다. 이와 더불어 망막모세포종의 재발률 증가도 망막모세포종 치료 시장에서 유망한 기회를 창출하고 있습니다. 또한 주요 결제 주체들의 파트너십 및 제휴, 인수합병(M&A)과 같은 다양한 유기적 성장 전략도 시장의 성장 동력이 되고 있습니다. 이 외에도 강력한 개발 파이프라인의 존재와 임상 시험의 증가도 시장 성장을 촉진하고 있습니다. 기타 시장 성장에 기여하는 요인으로는 급속한 도시화, 가처분 소득의 증가, 암 연구의 눈부신 발전, 그리고 세계 의료 인프라의 개선 등을 들 수 있습니다.
이 보고서에서 답변하는 주요 질문:
- 세계 망막모세포종 치료제 시장은 지금까지 어떤 추세를 보였으며, 향후 수년간 어떻게 변화하는가?
- 세계의 망막모세포종 치료제 시장 촉진요인, 제약 요인 및 기회는 무엇인가?
- 주요 지역 시장은 어디인가?
- 가장 매력적인 망막모세포종 치료제 시장을 형성하고 있는 국가는 어디인가?
- 치료 유형별 시장 현황은?
- 치료법별 시장 현황은?
- 병기별 시장 분류에 따른 시장 내역은?
- 용도에 따른 시장 내역은?
- 세계의 망막모세포종 치료제 시장의 경쟁 구조는 어떠한가?
- 세계의 망막모세포종 치료제 시장의 주요 플레이어/기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 개요
제4장 서론
제5장 세계의 망막아세포종 치료 시장
제6장 시장 내역 : 유형별
제7장 시장 내역 : 치료 유형별
제8장 시장 내역 : 스테이징 유형별
제9장 시장 내역 : 용도별
제10장 시장 내역 : 지역별
제11장 촉진요인·억제요인·기회
제12장 밸류체인 분석
제13장 Porters Five Forces 분석
제14장 가격 분석
제15장 경쟁 구도
KSA 26.05.19The global retinoblastoma treatment market size was valued at USD 3.1 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 4.2 Billion by 2034, exhibiting a CAGR of 3.38% from 2026-2034. Asia Pacific currently dominates the market. A significant increase in healthcare expenditure for ophthalmic treatment procedures, increased investments in R&D activities on therapies with lower side effects, and the growing health consciousness are some of the major factors driving the market in this region.
Retinoblastoma is one of the most common cancers that generally develops before the age of 5 in children. Some of the symptoms of retinoblastoma include a white appearance in the pupil called cat's eye reflex or leukocoria. Retinoblastoma treatment can include a variety of drug delivery and chemotherapy techniques that provide some benefits in the short term since retinoblastoma is curable at the initial stage. Following the first or second chemotherapy cycle, different focal treatments can then be applied depending on how much the tumor shrinks and where it is in the eye. A combination of different treatment methods is the most successful retinoblastoma treatment option. Surgery is the permanent retinoblastoma treatment option as it removes the tumor thoroughly from the retina. There are a variety of imaging tests available for a detailed diagnosis of retinoblastoma, including ultrasound, CT-scan, MRI, X-ray, and bone scan.
Retinoblastoma Treatment Market Trends:
A considerable rise in healthcare expenditure for ophthalmic treatment procedures is a significant factor driving the market. This can be attributed to the rising incidences of retinoblastoma among the younger population. In line with this, increasing investments in research and development (R&D) activities focusing on newer, more efficient therapeutic strategies with lesser associated side effects is providing an impetus to the market. Moreover, the growing awareness regarding different type of cancers resulting in higher diagnosis and treatment rates are also acting as a significant growth-inducing factor. However, the lack of availability of various retinoblastoma treatment drugs, along with stringent drug regulations, are acting as a growth-restraining factor for the market. On the contrary, the increasing number of product approvals leading to the launches of new drug variants is creating a positive outlook for the market. Besides this, the growing rates of recurrence of retinoblastoma are also creating lucrative opportunities in the retinoblastoma treatment market. The market is further propelled by various organic growth strategies undertaken by key payers, such as partnerships and collaborations, and merger and acquisitions (M&As). Apart from this, the presence of strong pipeline drugs, along with the augmenting number of clinical trials, are fueling the market growth. Some of the other factors contributing to the market include rapid urbanization, inflating disposable income levels, considerable growth in cancer research, and improvements in medical infrastructure across the globe.
Key Market Segmentation:
This report provides an analysis of the key trends in each segment of the global retinoblastoma treatment market, along with forecasts at the global, regional, and country level from 2026-2034. The report has categorized the market based on type, treatment type, type of staging, and application.
Type Insights:
- Non-Hereditary Retinoblastoma
- Hereditary Retinoblastoma
Treatment Type Insights:
- Surgery
- Radiation Therapy
- Laser Therapy (Photocoagulation)
- Cryotherapy
- Thermotherapy
- Chemotherapy
- Opthalmic Artery Infusion Chemotherapy
- High-Dose Chemotherapy and Stem Cell Transplant
Type of Staging Insights:
- Intraocular Retinoblastoma
- Extraocular Retinoblastoma
Application Insights:
- Hospitals
- Cancer Institutes
- Others
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific was the largest market for retinoblastoma treatment. Some of the factors driving the Asia Pacific retinoblastoma treatment market include the growing rates of recurrence of retinoblastoma, higher diagnosis and treatment rates due to the increasing awareness regarding different types of cancers, the presence of several key players in the region, etc.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global retinoblastoma treatment market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Bristol Myers Squibb Company, Pfizer Inc., Teva Canada Limited (Teva Pharmaceutical Industries Ltd.), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report:
- How has the global retinoblastoma treatment market performed so far and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global retinoblastoma treatment market?
- What are the key regional markets?
- Which countries represent the most attractive retinoblastoma treatment markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the treatment type?
- What is the breakup of the market based on the type of staging?
- What is the breakup of the market based on application?
- What is the competitive structure of the global retinoblastoma treatment market?
- Who are the key players/companies in the global retinoblastoma treatment market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Retinoblastoma Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Non-Hereditary Retinoblastoma
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Hereditary Retinoblastoma
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Treatment Type
- 7.1 Surgery
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Radiation Therapy
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Laser Therapy (Photocoagulation)
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Cryotherapy
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Thermotherapy
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Chemotherapy
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
- 7.7 Opthalmic Artery Infusion Chemotherapy
- 7.7.1 Market Trends
- 7.7.2 Market Forecast
- 7.8 High-Dose Chemotherapy and Stem Cell Transplant
- 7.8.1 Market Trends
- 7.8.2 Market Forecast
8 Market Breakup by Type of Staging
- 8.1 Intraocular Retinoblastoma
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Extraocular Retinoblastoma
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by Application
- 9.1 Hospitals
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Cancer Institutes
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Others
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 China
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 Germany
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 Drivers, Restraints, and Opportunities
- 11.1 Overview
- 11.2 Drivers
- 11.3 Restraints
- 11.4 Opportunities
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Bristol Myers Squibb Company
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Pfizer Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 Teva Canada Limited (Teva Pharmaceutical Industries Ltd.)
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.1 Bristol Myers Squibb Company
